BLACK WEEKSFlacoane −15% · kituri −10% · restul −5%cu codulLivrare gratuită în Germania de la 200 €

Această pagină a fost tradusă automat și poate conține erori. Sunteți vorbitor nativ? Ne bucurăm să primim feedbackul și corecturile dumneavoastră.Trimiteți feedback

The Peptide Desk The Peptide Desk

Aceste informații au exclusiv scop de cercetare și educațional. Nu sunt recomandări medicale. Produsele nu sunt aprobate pentru uz uman. Pentru întrebări legate de sănătate, consultați un medic.

Lexicon

Eloralintide

A selective amylin analogue with a half-life of around two weeks: satiety through the amylin path, with strikingly little nausea at low doses in the trials.

8 min read 7 sources

Eloralintide vial with white powder and the black TPD label on a white podium, next to a large blue 3D model of a peptide chain in a bright lab
Phase 3 · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

Prefers AMY1
12 -fold

more potent at the amylin 1 receptor than at the calcitonin receptor (cell assay)4

Half-life
~14 days

12.9 to 15.3 days after a single dose, about twice as long as cagrilintide4

Body weight in phase 2
-20.1 %

after 48 weeks, highest study level (placebo -0.4%)2

Pulse in phase 1
-14.4 beats/min

after 12 weeks, highest level (placebo -3.4), without symptoms from a slow pulse3

In phase 3
7 trials

five with eloralintide alone, two as a combination with tirzepatide (as of 26 Oct 2026)6

  • Eloralintide is a long-acting amylin analogue. It prefers the amylin 1 receptor and acts on the calcitonin receptor about twelve times more weakly.4
  • A fatty acid binds it to albumin. The half-life is therefore about two weeks. In the trials it is injected once a week.43
  • In the phase 2 trial with 263 adults weight fell by 9.4 to 20.1 percent after 48 weeks depending on the level, by 0.4 percent on placebo.12
  • Nausea and fatigue rose with the dose. In phase 1 the pulse fell, unlike with GLP-1 agonists. A few participants reported low mood.135
  • Phase 3 trials have been running since December 2025, there is no approval. Everything here is research, not a recommendation.6
Profil

Updated October 2026

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~14 days

Half-life ~14 days
After 28 days: 25 %
Day 14 · 50 %Day 28 · 25 %Day 42 · 12.5 %Day 70 · 3.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon. The lexicon gives 13 to 15 days, we calculate with the middle.

Class
Selective amylin receptor agonist

prefers AMY1R

Route
Subcutaneous

once weekly

Half-life
around 13 to 15 days
Status
Clinical research

phase 3 running since late 2025, not approved

Form
Lyophilised powder

reconstituted with BAC water

Sizes
10 mg

1 size in the shop

Cuprins 15 sections
  1. Pe scurt
  2. What is Eloralintide?
  3. How it works
  4. What you need
  5. Reconstitution
  6. Injection
  7. Use and dosing
  8. What the research shows
  9. Stadiul cercetării
  10. Side effects
  11. Storage
  12. Compuși înrudiți
  13. Întrebări frecvente
  14. Glosar
  15. Surse

What is Eloralintide?

Eloralintide (development name LY3841136) is a long-acting analogue of amylin, the hormone the pancreas releases together with insulin to tell the brain that food has arrived. It comes out of Eli Lilly's pipeline and sits next to cagrilintide among the once-weekly amylin analogues. The difference is in the receptor profile: eloralintide prefers the amylin 1 receptor and activates the calcitonin receptor far less, while cagrilintide is non-selective and activates the calcitonin receptor as well.

The molecule is a linear peptide carrying a C20 fatty acid at position 26, which binds it to albumin. That gives a half-life of around 13 to 15 days, roughly twice that of cagrilintide. It is injected subcutaneously once a week and ships as a freeze-dried powder in a 10mg vial that you dissolve in bacteriostatic water.

Eloralintide is not approved. The phase 2 data came out in late 2025. The first phase 3 trials have been running since then. There are no long-term data beyond 48 weeks yet.

This information is for research and educational purposes only. No medical advice.

Comparison

One, two or three receptors

Which receptors each compound targets, as stated in the TPD lexicon. Tap a card to open its entry.

In cell assays eloralintide also activates the calcitonin receptor, but about twelve times more weakly than the amylin 1 receptor. That is why it is listed under amylin only. 4

How it works

Amylin acts mainly in the brainstem and the hypothalamus. There it signals that a meal is under way: fullness sets in earlier and lasts longer. The urge to eat between meals drops. Amylin also curbs glucagon release after eating and slows gastric emptying. GLP-1 compounds use a different path, which is why research treats the amylin route as a complement rather than a copy.

Amylin receptors are composite receptors built from the calcitonin receptor plus a helper protein (RAMP). In cell assays eloralintide activates the human AMY1R roughly twelve times more strongly than the plain calcitonin receptor and roughly eleven times more strongly than the AMY3R. The developers' working hypothesis: less activation at the calcitonin receptor means less nausea for the same satiety. In rats eloralintide did cause less taste aversion than cagrilintide. In phase 2 nausea at 1 and 3mg sat at placebo level.

One observation stands apart from the incretin class: pulse rate dropped from the first week on and after 12 weeks at 12mg sat around 14 beats per minute below baseline on average (placebo around 3), instead of rising as it does under GLP-1 agonists. In rats, the weight lost also came mainly from fat mass. Studies suggest this could add up to a distinct cardiovascular profile, but so far that rests on surrogate markers only.

Where it acts

Amylin path, several organs

Tap a point or a card. Colour = receptor, grey = effect seen in trials.

  1. Brain

    Less food intake in rats, satiety via amylin receptors4

    Amylin
  2. Stomach

    Gastric emptying slowed at first, back close to baseline after 12 weeks (paracetamol test)3

    Observed in trials
  3. Fat tissue

    Weight loss in rats mainly from fat mass4

    Observed in trials
  4. Heart

    Pulse at the highest level down by 14.4 beats per minute after 12 weeks (placebo 3.4)3

    Observed in trials

Known targets4

Compound CHEMBL6068462: three described targets, type of action on each card.

Amylin receptor 1 (AMY1)
Gene
CALCR + RAMP1
UniProt
P30988, O60894
ChEMBL
CHEMBL2111189
Action
Full agonist, preferred target
Amylin receptor 3 (AMY3)
Gene
CALCR + RAMP3
UniProt
P30988, O60896
ChEMBL
CHEMBL2111190
Action
Full agonist, about eleven times weaker than at AMY1
Calcitonin receptor (CTR)
Gene
CALCR
UniProt
P30988
ChEMBL
CHEMBL1832
Action
Full agonist, about twelve times weaker than at AMY1
Glass nerve cell with a glowing centre, blue 3D peptide chains docking at two binding sites
Symbolic image.

What you need

The list is the same as for the other weekly peptides:

Supplies

5 things, numbered as in the picture

Tick off what you already have. Vial and BAC water are our real shop photos at the same size.

Eloralintide vial and bacteriostatic water at the same size with the black TPD label, next to two U-100 insulin syringes, two alcohol swabs and a sharps container with a blue lid
  1. Eloralintide vial

    The Eloralintide vial with the freeze-dried powder

    In the shop
  2. Bacteriostatic water

    Bacteriostatic water to dissolve it

    In the shop
  3. U-100 insulin syringes

    U-100 insulin syringes

  4. Alcohol swabs

    Alcohol swabs for the vial cap and the skin

  5. Sharps container

    A sealable sharps container for used needles

As an Amazon associate we earn from qualifying purchases. Links open Amazon - no extra cost for you.

A 1ml syringe (100 units) covers every step up to 3mg. With 2ml of water in the 10mg vial each step lands on whole units, so you do not need half-unit marks.

Reconstitution

The powder is dissolved in bacteriostatic water. The volume of water sets the concentration and with it the units you later draw for your dose on the insulin syringe. With 2ml on 10mg you get 5mg per ml: 0.5mg is then 10 units, 1mg 20, 2mg 40 and 3mg 60 units.

The peptide calculator works this out for any water volume: pick the vial size and the water. The concentration and units per dose then appear straight away. For the small starting doses, 2 or 3ml are more comfortable than 1ml, otherwise the dose gets tiny and hard to read.

Just add the bac water to the vial, it does not matter if it hits the powder directly. Then swirl or shake until everything is clearly dissolved, both are fine.

Step by step

Dissolving the powder

Four steps, the same for every vial size.

  1. 1Wipe the cap

    Clean the rubber stopper with an alcohol swab.

  2. 2Add BAC water

    Just add it, it does not matter if it hits the powder directly.

  3. 3Swirl or shake

    Until everything has dissolved, both are fine.

  4. 4Draw up

    With the U-100 insulin syringe.

Less water higher concentration fewer units on the syringe Example: 10 mg + 2 ml = 5 mg/ml

Injection

The injection is subcutaneous, into the fat layer under the skin, classically the abdomen (keep about two finger-widths clear of the navel), the front and the inner side of the thigh or the back of the upper arm.

Injection

Where and at what angle

Pick a spot or switch the angle. Subcutaneous means: into the fat layer, not the muscle.

Rotate the spot each time, never the same one twice in a row.

90°More fat under the skin

Rule of thumb: where there is more fat under the skin, insert straight at 90 degrees. In lean people with little fat, 45 degrees, so the needle stays in the fat layer. Simplified diagram.

  1. Clean the spot with an alcohol swab and let it dry

  2. Pinch up a small fold of skin

  3. Insert the needle: at 90 degrees where there is more fat under the skin, at 45 degrees in lean people with little fat

  4. Inject, slowly or briskly both work, wait a moment, then withdraw

  5. Put the needle straight into the sharps container

Rotate the site from week to week. In the phase 1 study, injection site reactions (mostly pain) were more frequent than under placebo from 3mg upwards; rotating sites and a clean injection keep that small.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

What the research shows

The development paper (Briere 2025) describes the receptor selectivity, the animal data and a single-dose study in 48 healthy volunteers with 0.04 to 12mg: well tolerated up to the highest dose, half-life of 13 to 15 days. Four weeks after a single 12mg dose body weight was 4.4 percent lower. The multiple-dose phase 1 study (Bhattachar 2026) ran for 12 weeks in 100 participants with overweight or obesity; the active groups received 1.2 to 12mg weekly without titration, the rest placebo. Weight fell by 2.6 to 11.3 percent depending on dose, only 8 percent reported nausea and 10 percent diarrhoea.

The phase 2 trial (Billings 2025, The Lancet) ran for 48 weeks in 263 adults with obesity or overweight and no diabetes. Weight fell by 9 percent at 1mg, 12 percent at 3mg, 18 percent at 6mg and 20 percent at 9mg, versus 0.4 percent under placebo. The escalation from 3 to 9mg reached 16 percent, the one from 6 to 9mg 20 percent. The effect was clearly dose-dependent, but the trial was limited to 48 weeks. What happens after that is open.

A review (Sigalov 2026) sums up the cardiovascular data: pulse rate, blood pressure, high-sensitivity CRP and lipids came down in the early studies. The authors single out the falling pulse rate, because GLP-1 agonists tend to raise heart rate. No amylin analogue has a cardiovascular outcomes trial, so the authors explicitly rate these findings as preliminary. The studies with links are in the source block below.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Weight change after 48 weeks2

Mean change in percent, 263 adults with obesity or overweight without diabetes

Fixed levels2 Four levels from lowest to highest
Placebo -0.4%
Lowest level -9.4%
Second level -12.4%
Third level -17.6%
Highest level -20.1%
With step-up2 Slowly increased to the highest level
Placebo -0.4%
Step-up from level 3 to the highest -19.9%
Step-up from level 2 via 3 to the highest -16.5%

Values from the results section of the registry, rounded to whole percent in the abstract (9 to 20 percent). The trial ran for 48 weeks, what happens after that is open.

Share with at least 10 percent weight loss2

After 48 weeks, in percent of participants

Fixed levels2
Placebo 12.9%
Lowest level 53.3%
Second level 60.5%
Third level 76.6%
Highest level 82.3%
With step-up2
Placebo 12.9%
Step-up from level 3 to the highest 91.1%
Step-up from level 2 via 3 to the highest 79.2%

Rounded from the values in the registry (for example 82.32 percent). On placebo about 13 in 100 reached it.

Pulse change after 12 weeks3

Mean change in beats per minute, phase 1 with 100 participants

Resting pulse3 Without titration, once a week
Placebo -3.4%
Phase 1: second level -7.1%
Phase 1: third level -8.3%
Phase 1: highest level -14.4%

The pulse fell within the first week. Nobody reported symptoms from a pulse that was too slow. GLP-1 agonists, by contrast, tend to raise heart rate. There is no cardiovascular outcomes trial for any amylin analogue.

Glass cross-section model of a stomach wall with reddish folds and muscle layers on a bright surface
Symbolic image.

Research status

Where the research stands

Registered trials with status, participants and results. As of 26 Oct 2026. 6

  1. Preclinical Cell assays on amylin and calcitonin receptors, rats and monkeys
  2. Phase 1 12 trials, 5 completed
  3. Phase 2 5 trials, 2 completed
  4. Phase 3 7 trials, 0 completed
  5. Approval not yet
5,615 participants in phase 3 Planned figures for running trials Not approved yet. According to the registry the first phase 3 results are expected in early 2028 at the earliest.6
Show all 12 phase 2 and 3 trials on a timelineHide timeline 2 completed 10 running 1 with results
Phase 2
Phase 3

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 12 trials on safety and pharmacokinetics, not shown as bars.

Side effects

Nausea is the most common side effect, but strongly dose-dependent: in phase 2 it was 11 percent at 1mg and 13 percent at 3mg, against 14 percent under placebo. At 6mg it jumped to 64 percent, at 9mg it was 33 percent. Vomiting and diarrhoea were rare in phase 1 (4 and 10 percent). Tolerability at low doses is the real argument for the compound. It only holds as long as the dose stays low.

Fatigue rose with the dose in phase 2: 0 percent at 1mg, 13 percent at 3mg, 29 percent at 6mg, 43 percent at 9mg, against 12 percent under placebo. Add decreased appetite (that is the point), headache and injection site reactions from 3mg upwards. In the phase 1 study, four participants reported low mood, one at 6mg and three at 12mg. The three in the 12mg group stopped treatment. The complaints resolved within two to four days. That is a small but serious signal for high doses and one more reason to stay low.

Because the half-life is around two weeks, side effects do not fade in days after stopping but over weeks. Whoever steps up too fast keeps the nausea for just as long. Long-term data beyond 48 weeks are missing. There are no data on pregnancy, children or pre-existing conditions.

Tolerability

Nausea and fatigue in phase 2

Out of 100 participants per group, how many had the event over 48 weeks.

14 of 100 Placebo
11 of 100 Lowest level
13 of 100 Second level
64 of 100 Third level
33 of 100 Highest level
54 of 100 Step-up from level 3 to the highest
25 of 100 Step-up from level 2 via 3 to the highest
Event PlaceboLowest levelSecond levelThird levelHighest levelStep-up from level 3 to the highestStep-up from level 2 via 3 to the highest
Nausea1 14%11%13%64%33%54%25%
Fatigue1 12%0%13%29%43%46%21%

In the two lowest levels nausea was at placebo level. In phase 1 gastrointestinal effects were rare (nausea 8, diarrhoea 10, vomiting 4 percent). Four participants reported low mood, three of them at the highest level stopped, the symptoms resolved in two to four days.13

Storage

The undissolved powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept dark and dry. For longer periods it can also go in the fridge.

Once mixed, it keeps for at least 4 to 6 months in the fridge (2 to 8 °C). The bacteriostatic water brings a preservative that keeps the dissolved form stable. With a 10mg vial and 0.5 to 1mg per week, one vial lasts ten to twenty weeks. The solution stays usable long enough for that.

Do not freeze it and do not leave it in the sun. If the solution turns gel-like or lumpy, do not use the vial. A slight cloudiness on its own is no reason to discard it.

Shelf life

How long it keeps

Undissolved (powder) Room temperature, around 20 to 25 degrees, dark and dry

Robust, no fridge needed. Keeps for several months without trouble.

Dissolved (mixed) Fridge, 2 to 8 degrees, do not freeze

Keeps for at least 4 to 6 months. The bacteriostatic water brings a preservative.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder dark at room temperature, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months, do not freeze. Symbolic image.
Level · Eloralintide

Cum se acumulează nivelul

One dose per week: fiecare doză se adaugă la ce a rămas din cea anterioară.

Peak 3.41×Trough 2.41×
Day 56 · 9. dose
3.26× of the first dose
Plateau
from Day 56

96 % of the plateau after dose 9

Peak
3.41×

of the first dose

Trough
2.41×

before the next dose

Model simplificat, valori relative la prima doză, fără informații de dozare. Linie punctată: doar prima doză, verde: platoul.

Related

Related compounds

Same receptors or a different path: all in the TPD lexicon.

FAQ

Common questions about Eloralintide

Short answers, each backed by the sources below.

Is eloralintide approved?

No. As of 26 October 2026 ClinicalTrials.gov lists seven phase 3 trials: five ENLIGHTEN trials with eloralintide alone (recruiting since December 2025) and two AMPLIFY trials with a combination of eloralintide and tirzepatide. The AMPLIFY trials have not started yet. First main results are planned for 2028.6

How does eloralintide differ from cagrilintide?

Mainly the receptor profile and the duration. In cell assays eloralintide activates the human amylin 1 receptor about twelve times more strongly than the calcitonin receptor, while cagrilintide acts on both. In rats eloralintide caused less taste aversion than cagrilintide. At 12.9 to 15.3 days the half-life is about twice as long.4

What did the phase 2 trial show?

263 adults with obesity or overweight without diabetes received one of four fixed levels, one of two step-up schemes or placebo for 48 weeks. Weight fell by 9.4 to 20.1 percent depending on the level, by 0.4 percent on placebo. Depending on the group 53 to 91 in 100 participants lost at least 10 percent, 13 on placebo.12

How long does eloralintide stay in the body?

After a single dose the half-life was 310 to 366 hours, so about two weeks. It reached its peak blood level only after three to five days. With weekly dosing the level therefore builds up over several weeks and falls just as slowly after stopping.4

Which side effects were seen?

Nausea and fatigue, both strongly dose-dependent: in the two lowest levels nausea was at placebo level at 11 and 13 percent (14 percent), at the third level 64 percent. Headaches and injection site reactions came on top. In phase 1 four participants reported low mood, three of them at the highest level stopped.13

What about the pulse and the heart?

In phase 1 resting pulse fell within the first week, at the highest level by 14.4 beats per minute after 12 weeks (placebo 3.4). There were no symptoms from a pulse that was too slow. A review sees this as a difference from GLP-1 agonists but stresses that no amylin analogue has had a cardiovascular outcomes trial.35

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Agonist
A substance that binds to a receptor and activates it, like the body's own messenger.
Albumin
The most common protein in the blood. A compound that binds to it is broken down more slowly and lasts longer.
Amylin
Hormone that the pancreas releases together with insulin. It slows gastric emptying and glucagon after meals and signals fullness to the brain.
Calcitonin receptor
Receptor that responds to calcitonin on its own and forms the amylin receptors together with a helper protein (RAMP).
Gastric emptying
The pace at which the stomach passes its contents on to the gut. Slower means you feel full for longer.
GLP-1
Glucagon-like peptide 1: gut hormone that releases insulin, slows gastric emptying and signals fullness in the brain. Semaglutide acts through this receptor.
Half-life
Time after which only half of a substance is left in the blood. At about two weeks it takes several weeks for the level to settle.
Lyophilisate
Freeze-dried powder. Without water a peptide keeps much longer.
Placebo
Dummy preparation without active substance. Comparing against it shows what is due to the substance itself.
RAMP
Helper protein in the cell membrane. With RAMP1 the calcitonin receptor becomes the amylin 1 receptor, with RAMP3 the amylin 3 receptor.
Trial phases
Phase 1 tests tolerability in a few people, phase 2 looks for the dose, phase 3 confirms benefit and safety in thousands. After that, approval can be requested.

Dovezi

Surse

Show all 7 sourcesHide sources 4 Studies2 Trial registry1 Database checked 26 Oct 2026

Studies

  1. 48-week phase 2 trial in obesity and overweight

    Billings et al., The Lancet, 2025

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Phase 1 multiple-dose trial over 12 weeks

    Bhattachar et al., Diabetes, Obesity and Metabolism, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  3. Discovery, receptor profile, animal data and first single dose in humans

    Briere et al., Molecular Metabolism, 2025

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  4. Review of the cardiovascular data on eloralintide

    Sigalov und Frishman, Cardiology in Review, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Results of the phase 2 trial on the trial registry

    ClinicalTrials.gov, NCT06230523, Ergebnisteil

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2
  2. All trials on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Eloralintide in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL6068462)

    Checked 26 Oct 2026 via ChEMBL

În magazin

Eloralintide in the catalog

Mărimile, prețurile și termenele de livrare se găsesc pe pagina produsului.

La produs